vs

Side-by-side financial comparison of AbbVie (ABBV) and Linde plc (LIN). Click either name above to swap in a different company.

AbbVie is the larger business by last-quarter revenue ($16.6B vs $8.8B, roughly 1.9× Linde plc). Linde plc runs the higher net margin — 17.5% vs 10.9%, a 6.5% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs 5.8%). AbbVie produced more free cash flow last quarter ($4.9B vs $1.6B). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 4.0%).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

ABBV vs LIN — Head-to-Head

Bigger by revenue
ABBV
ABBV
1.9× larger
ABBV
$16.6B
$8.8B
LIN
Growing faster (revenue YoY)
ABBV
ABBV
+4.2% gap
ABBV
10.0%
5.8%
LIN
Higher net margin
LIN
LIN
6.5% more per $
LIN
17.5%
10.9%
ABBV
More free cash flow
ABBV
ABBV
$3.3B more FCF
ABBV
$4.9B
$1.6B
LIN
Faster 2-yr revenue CAGR
ABBV
ABBV
Annualised
ABBV
16.2%
4.0%
LIN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABBV
ABBV
LIN
LIN
Revenue
$16.6B
$8.8B
Net Profit
$1.8B
$1.5B
Gross Margin
72.6%
Operating Margin
27.3%
23.0%
Net Margin
10.9%
17.5%
Revenue YoY
10.0%
5.8%
Net Profit YoY
8354.5%
-11.3%
EPS (diluted)
$1.02
$3.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABBV
ABBV
LIN
LIN
Q4 25
$16.6B
$8.8B
Q3 25
$15.8B
$8.6B
Q2 25
$15.4B
$8.5B
Q1 25
$13.3B
$8.1B
Q4 24
$15.1B
$8.3B
Q3 24
$14.5B
$8.4B
Q2 24
$14.5B
$8.3B
Q1 24
$12.3B
$8.1B
Net Profit
ABBV
ABBV
LIN
LIN
Q4 25
$1.8B
$1.5B
Q3 25
$186.0M
$1.9B
Q2 25
$938.0M
$1.8B
Q1 25
$1.3B
$1.7B
Q4 24
$-22.0M
$1.7B
Q3 24
$1.6B
$1.6B
Q2 24
$1.4B
$1.7B
Q1 24
$1.4B
$1.6B
Gross Margin
ABBV
ABBV
LIN
LIN
Q4 25
72.6%
Q3 25
66.4%
Q2 25
71.8%
Q1 25
70.0%
Q4 24
70.9%
Q3 24
70.9%
Q2 24
70.9%
Q1 24
66.7%
Operating Margin
ABBV
ABBV
LIN
LIN
Q4 25
27.3%
23.0%
Q3 25
12.1%
27.5%
Q2 25
31.7%
27.7%
Q1 25
28.0%
26.9%
Q4 24
-9.9%
27.4%
Q3 24
26.5%
25.0%
Q2 24
27.6%
26.4%
Q1 24
22.7%
25.9%
Net Margin
ABBV
ABBV
LIN
LIN
Q4 25
10.9%
17.5%
Q3 25
1.2%
22.4%
Q2 25
6.1%
20.8%
Q1 25
9.6%
20.6%
Q4 24
-0.1%
20.8%
Q3 24
10.8%
18.5%
Q2 24
9.5%
20.1%
Q1 24
11.1%
20.1%
EPS (diluted)
ABBV
ABBV
LIN
LIN
Q4 25
$1.02
$3.28
Q3 25
$0.10
$4.09
Q2 25
$0.52
$3.73
Q1 25
$0.72
$3.51
Q4 24
$-0.03
$3.61
Q3 24
$0.88
$3.22
Q2 24
$0.77
$3.44
Q1 24
$0.77
$3.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABBV
ABBV
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$5.3B
$5.1B
Total DebtLower is stronger
$58.9B
$20.7B
Stockholders' EquityBook value
$-3.3B
$38.2B
Total Assets
$134.0B
$86.8B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABBV
ABBV
LIN
LIN
Q4 25
$5.3B
$5.1B
Q3 25
$5.7B
$4.5B
Q2 25
$6.5B
$4.8B
Q1 25
$5.2B
$5.3B
Q4 24
$5.6B
$4.8B
Q3 24
$7.3B
$5.2B
Q2 24
$13.2B
$4.6B
Q1 24
$18.1B
$4.8B
Total Debt
ABBV
ABBV
LIN
LIN
Q4 25
$58.9B
$20.7B
Q3 25
$63.0B
$18.6B
Q2 25
$63.0B
$19.7B
Q1 25
$64.5B
$17.6B
Q4 24
$60.3B
$15.3B
Q3 24
$58.5B
$17.5B
Q2 24
$58.0B
$16.9B
Q1 24
$63.8B
$15.2B
Stockholders' Equity
ABBV
ABBV
LIN
LIN
Q4 25
$-3.3B
$38.2B
Q3 25
$-2.6B
$38.6B
Q2 25
$-183.0M
$38.5B
Q1 25
$1.4B
$38.0B
Q4 24
$3.3B
$38.1B
Q3 24
$6.0B
$39.2B
Q2 24
$6.8B
$38.2B
Q1 24
$8.0B
$38.8B
Total Assets
ABBV
ABBV
LIN
LIN
Q4 25
$134.0B
$86.8B
Q3 25
$133.9B
$86.0B
Q2 25
$137.2B
$86.1B
Q1 25
$136.2B
$82.7B
Q4 24
$135.2B
$80.1B
Q3 24
$143.4B
$82.5B
Q2 24
$141.9B
$80.2B
Q1 24
$148.9B
$80.3B
Debt / Equity
ABBV
ABBV
LIN
LIN
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
45.44×
0.46×
Q4 24
18.15×
0.40×
Q3 24
9.70×
0.45×
Q2 24
8.56×
0.44×
Q1 24
7.97×
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABBV
ABBV
LIN
LIN
Operating Cash FlowLast quarter
$5.2B
$3.0B
Free Cash FlowOCF − Capex
$4.9B
$1.6B
FCF MarginFCF / Revenue
29.4%
17.9%
Capex IntensityCapex / Revenue
2.0%
16.6%
Cash ConversionOCF / Net Profit
2.87×
1.98×
TTM Free Cash FlowTrailing 4 quarters
$17.8B
$5.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABBV
ABBV
LIN
LIN
Q4 25
$5.2B
$3.0B
Q3 25
$7.0B
$2.9B
Q2 25
$5.2B
$2.2B
Q1 25
$1.6B
$2.2B
Q4 24
$7.0B
$2.8B
Q3 24
$5.4B
$2.7B
Q2 24
$2.3B
$1.9B
Q1 24
$4.0B
$2.0B
Free Cash Flow
ABBV
ABBV
LIN
LIN
Q4 25
$4.9B
$1.6B
Q3 25
$6.6B
$1.7B
Q2 25
$4.9B
$954.0M
Q1 25
$1.4B
$891.0M
Q4 24
$6.8B
$1.6B
Q3 24
$5.2B
$1.7B
Q2 24
$2.0B
$796.0M
Q1 24
$3.8B
$906.0M
FCF Margin
ABBV
ABBV
LIN
LIN
Q4 25
29.4%
17.9%
Q3 25
42.1%
19.4%
Q2 25
31.7%
11.2%
Q1 25
10.5%
11.0%
Q4 24
44.7%
18.8%
Q3 24
35.9%
19.9%
Q2 24
14.0%
9.6%
Q1 24
31.3%
11.2%
Capex Intensity
ABBV
ABBV
LIN
LIN
Q4 25
2.0%
16.6%
Q3 25
2.4%
14.8%
Q2 25
1.7%
14.8%
Q1 25
1.8%
15.7%
Q4 24
1.9%
15.1%
Q3 24
1.7%
12.8%
Q2 24
1.7%
13.7%
Q1 24
1.6%
12.9%
Cash Conversion
ABBV
ABBV
LIN
LIN
Q4 25
2.87×
1.98×
Q3 25
37.76×
1.53×
Q2 25
5.49×
1.25×
Q1 25
1.27×
1.29×
Q4 24
1.63×
Q3 24
3.49×
1.76×
Q2 24
1.66×
1.16×
Q1 24
2.95×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABBV
ABBV

Segment breakdown not available.

LIN
LIN

Other$4.9B56%
Packaged Gas$1.6B19%
Merchant$1.2B14%
On Site$950.0M11%
Other Distribution Methods$64.0M1%

Related Comparisons